Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been imp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Bhatti, Maria, Ippolito, Thomas, Mavis, Cory, Gu, Juan, Cairo, Mitchell S., Lim, Megan S., Hernandez-Ilizaliturri, Francisco, Barth, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955151/
https://ncbi.nlm.nih.gov/pubmed/29774105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25072
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares